Advertisement
Singapore markets open in 3 hours 51 minutes
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Bitcoin USD

    64,060.40
    -2,291.13 (-3.45%)
     
  • CMC Crypto 200

    1,385.35
    -38.75 (-2.72%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Gold

    2,329.00
    -13.10 (-0.56%)
     
  • Crude Oil

    82.81
    -0.55 (-0.66%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?

Abbott Laboratories (NYSE: ABT) has generally been a good investment to hold over the years. Is Abbott a bad-news buy that could turn things around in 2023, or has this once-safe healthcare stock become too risky of an investment to be holding right now? Last month, Abbott reported its fourth-quarter and year-end results for 2022.